Clomiphene vs Enclomiphene: Which SERM for PCT?

Clomiphene citrate (Clomid) and enclomiphene are both selective estrogen receptor modulators (SERMs) used to stimulate LH and FSH production in men with suppressed HPTA function. They are the two most commonly used pharmaceutical agents for PCT and treatment of secondary hypogonadism in AAS users. However, they are not equivalent compounds.

Clomiphene citrate is a racemic mixture of two geometric isomers in approximately a 60:40 ratio:

• Enclomiphene (trans-isomer, approximately 60%): the active LH/FSH-stimulating component; a pure estrogen receptor antagonist at the hypothalamus and pituitary
• Zuclomiphene (cis-isomer, approximately 40%): a weak estrogen receptor agonist at many tissues; responsible for most of clomiphene's undesirable side effects

Enclomiphene (also sold as Androxal) is the pure trans-isomer. By isolating the active isomer and removing zuclomiphene, enclomiphene delivers the LH/FSH stimulation without the estrogenic agonist side effects at the liver (SHBG elevation), pituitary, and other tissues where zuclomiphene acts as a partial agonist.

Composition and mechanism:

• Clomiphene: 60% enclomiphene + 40% zuclomiphene. The two isomers have opposing receptor activities, creating a compound with mixed agonist/antagonist properties depending on the tissue.
• Enclomiphene: 100% trans-isomer. Pure estrogen receptor antagonist at the hypothalamus and pituitary, with no meaningful estrogenic agonist activity at peripheral tissues.

Effect on SHBG:

• Clomiphene raises SHBG by 15-25% at standard doses, driven primarily by zuclomiphene's estrogenic activity at the liver. This reduces free testosterone even as total testosterone improves.
• Enclomiphene has minimal effect on SHBG because it lacks zuclomiphene's hepatic estrogenic agonism. Free testosterone rises in proportion to the total testosterone increase.

LH and FSH stimulation:

• Both compounds stimulate LH and FSH effectively at equivalent doses. The LH/FSH-stimulating effect is carried primarily by the enclomiphene fraction in clomiphene, so the gonadotropin response per milligram of active isomer is comparable.
• Enclomiphene doses of 12.5-25 mg/day produce LH/FSH stimulation equivalent to clomiphene 25-50 mg/day.

Half-life and clearance:

• Enclomiphene has a shorter half-life (approximately 10-12 hours) than zuclomiphene (approximately 30 days). This means enclomiphene clears from the body within days of stopping, whereas zuclomiphene accumulates with clomiphene use and persists for weeks to months.
• The prolonged zuclomiphene half-life means clomiphene side effects can persist well after the dose is stopped, while enclomiphene's effects resolve quickly.

Side effect profile:

• Clomiphene's visual disturbances (blurred vision, floaters, light sensitivity) are attributed to zuclomiphene accumulating in the retina over time. These are rare but can be permanent in severe cases.
• Mood changes (anxiety, irritability, emotional lability) associated with clomiphene are also linked to zuclomiphene's mixed estrogenic activity in the CNS.
• Enclomiphene produces neither visual disturbances nor the estrogenic CNS effects associated with zuclomiphene. Most users report a cleaner, more predictable experience.

Evidence base:

• Clomiphene has decades of clinical data in male hypogonadism and extensive community use in PCT, providing a large real-world safety and efficacy database.
• Enclomiphene has a smaller but growing clinical evidence base. Phase 2/3 trials (Repros Therapeutics) demonstrated equivalence to testosterone gel for raising serum testosterone in secondary hypogonadism, with the significant advantage of preserving spermatogenesis.
• Enclomiphene is not FDA-approved but is available through compounding pharmacies and telehealth prescribers in many countries.

Dosing:

• Clomiphene standard PCT dosing: 50 mg/day for weeks 1-2, 25 mg/day for weeks 3-4.
• Enclomiphene standard dosing: 12.5-25 mg/day throughout therapy. Some protocols use 25 mg/day for the first 2-4 weeks then taper to 12.5 mg/day.

Choose enclomiphene when:

• It is accessible and affordable (availability varies by country; compounding pharmacy cost can be higher than generic clomiphene)
• SHBG elevation during clomiphene is a concern (men with already elevated SHBG will find enclomiphene meaningfully superior)
• Previous clomiphene use caused visual disturbances or significant mood side effects
• A clean, predictable pharmacokinetic profile is preferred (fast clearance, no zuclomiphene accumulation)
• Fertility preservation is a priority (both preserve spermatogenesis, but enclomiphene's cleaner profile makes monitoring simpler)

Choose clomiphene when:

• Enclomiphene is unavailable or cost-prohibitive
• You have a track record of tolerating clomiphene without significant side effects
• Your prescriber is more familiar with clomiphene and can monitor appropriately
• Generic clomiphene cost is a primary consideration (it is significantly cheaper than compounded enclomiphene in most markets)

Neither is appropriate when:

• LH fails to rise at 6 weeks on therapy (suggesting primary testicular failure or compound still suppressing; add HCG or refer to endocrinology)
• Tamoxifen (another SERM) is preferred for concurrent gynecomastia management (tamoxifen has direct anti-gynecomastia activity that clomiphene and enclomiphene lack)